RedHill Biopharma (RDHL) Regains Nasdaq Compliance

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received confirmation from the Listings Qualifications Department of The Nasdaq Stock Market LLC (the "Listings Qualifications Department") that the Company had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market ("Nasdaq"), and is now compliant with applicable listing standards for continued Nasdaq listing. To regain compliance with Nasdaq Listing Rule 5550(a)(2), the Company was required to maintain a minimum closing bid price for its American Depositary Shares (the "ADSs") of $1.00 per share or more for at least 10 consecutive business days, which was achieved on September 3, 2024.

You May Also Be Interested In

• Chardan Assumes Rocket Pharmaceuticals (RCKT) at Buy
• Kanzhun appoints Tao Zhang as rotating president effective Sept. 1
• Comstock Resources signs $1.65B deal with SOCAR, $450M JV